Phase 3 Clinical Trials With Primary Completion Dates in March 2023
This is a list of Phase 3 trials with primary completion dates in March 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2023-03-01 | Phase 3 | NCT04531982 | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia |
| ALLK | Allakos Inc. | 2023-03-01 | Phase 3 | NCT04620811 | An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) |
| CING | Cingulate Inc. | 2023-03-01 | Phase 3 | NCT05631626 | Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301. |
| EBS | Emergent BioSolutions Inc. | 2023-03-01 | Phase 3 | NCT05072080 | A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 |
| KOD | Kodiak Sciences Inc. | 2023-03-01 | Phase 3 | NCT04964089 | A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) |
| KPTI | Karyopharm Therapeutics Inc. | 2023-03-01 | Phase 3 | NCT03555422 | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] |
| OPHLY | Ono Pharmaceutical Co., Ltd. | 2023-03-01 | Phase 3 | NCT03006705 | Study of Adjuvant ONO-4538 With Resected Gastric Cancer |
| PYPD | PolyPid Ltd. | 2023-03-01 | Phase 3 | NCT04411199 | D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II) |